Evaluation of Stigma Toward Fatty Liver Disease
A part of our concern about fatty liver disease awareness without trivialization. The use of the word "fat" in the nomenclature of fatty liver disease linked with metabolic dysfunction is not perceived to be stigmatizing. The suggested change to MASLD does not seem warranted, at least if the stigma is the main concern.
Authors
- Ziyan Pan (ORCID: https://orcid.org/0000-0001-8365-5712)
- Yasser Fouad (ORCID: https://orcid.org/0000-0001-7989-5318)
- Shaker Wagih Shaltout (ORCID: https://orcid.org/0000-0002-4304-3276)
- Mohamed Alboraie (ORCID: https://orcid.org/0000-0002-8490-9822)
- Shaymaa Nafady (ORCID: https://orcid.org/0000-0002-8207-2934)
- Alaa Mohamed Mostafa (ORCID: https://orcid.org/0000-0002-1237-8428)
- Hany Samir Rasmy (ORCID: https://orcid.org/0000-0002-2902-6058)
- Mohammed Eslam
- Dalia Hassan (ORCID: https://orcid.org/0009-0002-3141-7936)
Institutions
- Ain Shams University (EG)
- Beni-Suef University (EG)
- The University of Sydney (AU)
- Al-Azhar University (EG)
- Westmead Hospital (AU)
- Westmead Institute (AU)
- Westmead Institute for Medical Research (AU)
- Alexandria University (EG)
- Port Said University (EG)
- Minia University (EG)
Publication Details
- Journal
- Endocrine Metabolic & Immune Disorders - Drug Targets
- Published
- 2025-05-06
- DOI
- https://doi.org/10.2174/0118715303359141250420070406
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00